Search research articles
Contact Us
Filters
Showing results (1-10 of 126) with videos related to
Page
of 13
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 20, 2025
Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China
Ying Liu, Xiaoning He
Current Medical Research and Opinion
|
December 27, 2017
Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China
Xiaoning He, Lizheng Shi, Jing Wu
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas
|
July 21, 2021
Oncogenic circDHTKD1 promotes tumor growth and metastasis of oral squamous cell carcinoma in vitro and in vivo via upregulating miR-326-mediated GAB1
Zhuangzhi Wu, Xiaoning He, Siqi Chen
JAMA Pediatrics
|
April 22, 2024
Enhancing the Interpretation of Continuous Outcomes and Subgroup Analyses in Systematic Reviews
Jing Wu, Qi Wang, Xiaoning He
Heart & Lung : the Journal of Critical Care
|
November 24, 2025
Medication management, health outcomes, and economic burden of severe asthma stratified by asthma control levels
Ke Zhang, Xiaoning He, Jing Wu
Clinical Drug Investigation
|
March 10, 2026
Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib
Xuefei Bai, Rongjie Shao, Xiaoning He
Frontiers in Public Health
|
April 11, 2022
The Impact of Hyperkalemia on Mortality and Healthcare Resource Utilization Among Patients With Chronic Kidney Disease: A Matched Cohort Study in China
Jiahui Zhang, Xiaoning He, Jing Wu
Applied Health Economics and Health Policy
|
April 28, 2022
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
Jia Liu, Xiaoning He, Jing Wu
Pharmacoeconomics
|
September 7, 2022
Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
Xinyue Dong, Xiaoning He, Jing Wu
Expert Review of Pharmacoeconomics & Outcomes Research
|
May 18, 2025
Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in China
Lei Gan, Xiaoning He, Jing Wu
Page
of 13
Search research articles
Search
Showing results (1-10 of 126) with videos related to
Sort By:
Page
of 13
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 20, 2025
Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China
Ying Liu, Xiaoning He
Current Medical Research and Opinion
|
December 27, 2017
Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China
Xiaoning He, Lizheng Shi, Jing Wu
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas
|
July 21, 2021
Oncogenic circDHTKD1 promotes tumor growth and metastasis of oral squamous cell carcinoma in vitro and in vivo via upregulating miR-326-mediated GAB1
Zhuangzhi Wu, Xiaoning He, Siqi Chen
JAMA Pediatrics
|
April 22, 2024
Enhancing the Interpretation of Continuous Outcomes and Subgroup Analyses in Systematic Reviews
Jing Wu, Qi Wang, Xiaoning He
Heart & Lung : the Journal of Critical Care
|
November 24, 2025
Medication management, health outcomes, and economic burden of severe asthma stratified by asthma control levels
Ke Zhang, Xiaoning He, Jing Wu
Clinical Drug Investigation
|
March 10, 2026
Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib
Xuefei Bai, Rongjie Shao, Xiaoning He
Frontiers in Public Health
|
April 11, 2022
The Impact of Hyperkalemia on Mortality and Healthcare Resource Utilization Among Patients With Chronic Kidney Disease: A Matched Cohort Study in China
Jiahui Zhang, Xiaoning He, Jing Wu
Applied Health Economics and Health Policy
|
April 28, 2022
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
Jia Liu, Xiaoning He, Jing Wu
Pharmacoeconomics
|
September 7, 2022
Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
Xinyue Dong, Xiaoning He, Jing Wu
Expert Review of Pharmacoeconomics & Outcomes Research
|
May 18, 2025
Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in China
Lei Gan, Xiaoning He, Jing Wu
Page
of 13